Healthcare
Abiomed, Inc.(ABMD)
Data coverage status ยท 6 need attention
Quote: Stale
Quote synced 2026-08-02T22:23:27.929802Z
Daily bars through 2022-12-23 ยท Stale
Daily bars synced 2026-07-03T20:20:20.212035Z
Fundamentals through 2026-05-04 ยท Delayed
Fundamentals synced 2026-05-18T20:32:47.306219Z
Forecasts: Missing
Forecasts synced 0001-01-01T00:00:00Z
Ownership: Missing
Ownership synced 2026-05-18T20:32:47.306219Z
Short interest: Missing
Short interest synced 2026-05-18T20:32:47.306219Z
News: Missing
News synced 0001-01-01T00:00:00Z
Company profile: Delayed
Company profile synced 2026-05-06T21:57:33.1761Z
Regular-session price
Offlineโ
1Y Change
โ
Window
No data
- Market Cap
- $17.18B
- P/E
- 126.8
- Trailing
- 52W Range
- $219.85 - $381.99
- Volume
- 15.70M
- 7.2x RVOL
Investment Snapshot
Valuation, growth, profitability, catalysts, and benchmark context.
1D
โ
1M
โ
6M
โ
YTD
โ
1Y
โ
- Market Cap
- $17.18B
- NASDAQ
- P/E
- 126.8
- Trailing valuation
- Revenue Growth
- +21.7%
- TTM growth
- EPS Growth
- -40.0%
- TTM earnings growth
- Operating Margin
- 36.1%
- TTM profitability
- Forward P/E
- โ
- Waiting on consensus EPS
- Next Earnings
- Nov 3, 2026
- In 90 days
- 52W Position
- --
- $219.85 - $381.99
- Volume
- 7.2x
- 15.70M shares latest
- Benchmark
- --
- vs SPY over 1Y
- Dividend
- $0.00 annual
- No dividend date in database
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Abiomed, Inc. (ABMD) is a Healthcare stock with listed on NASDAQ. Baseline metrics include revenue growth of +21.7%, EPS growth of -40.0%, a dividend yield of 0.0%. What stands out right now is revenue +21.7%, EPS -40.0%, free cash flow +12.9% with operating margin 36.1% and ROIC 17.4%. Valuation already assumes a fairly strong business story at P/E 126.8 and price/sales 16.7. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines ABMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+21.7% vs +6.2% peer median
Operating Margin
Above sector median
+36.1% vs +10.1% peer median
P/E
Above sector median
126.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2023 was reported on Nov 3, 2023, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +21.7% and EPS is at -40.0%, with operating margin around 36.1%.
The next real check-in already has a date
The next earnings event is scheduled for Nov 3, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Benchmark Edge
ABMD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ABMD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ABMD Max Drawdown
โ
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ABMD and SPY.
Company Overview
Abiomed, Inc.
NASDAQ Global Select
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
- Leadership
- Michael Minogue
- IPO Date
- Jul 29, 1987
- Employees
- 2.0k
- Street Address
- 22 CHERRY HILL DR
- Mailing
- Danvers, MA, 01923
- Region
- Danvers, MA, US
- Reporting Currency
- USD
- Investor Line
- 19787775410
- Last Updated
- May 6, 2026
Statistics & Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 126.8
- EV/EBITDA
- 34.1
- Price/Sales
- 16.7
- Price/Book
- 11.5
Growth
- Revenue
- +21.7%
- EPS
- -40.0%
- Free Cash Flow
- +12.9%
Profitability
- Gross Margin
- 81.8%
- Operating Margin
- 36.1%
- Net Margin
- 13.2%
- ROE
- 9.6%
- ROIC
- 17.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 7.05
Earnings Reports
Latest News
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.